(Reuters) -Siemens Healthineers on Wednesday reported fourth-quarter revenue that was slightly below analysts’ consensus as higher U.S. import tariffs weighed on sales.
The group’s revenue was 6.32 billion euros ($7.37 billion) in the quarter, compared to the 6.45 billion euros expected by analysts polled by Vara Research.
“Higher tariffs had a negative effect in all segments,” the company said in a statement, saying these were offset by revenue development and cost reductions in the diagnostics business.
The German medical technology company said it expects to face tariff-related costs of around 200 million euros this year and around 400 million euros in 2026.
In July Siemens Healthineers said it expected U.S. tariffs to have an impact between 400-500 million euros in 2026.
The group’s full-year comparable revenue growth of 5.9% came in at the top end of its annual guidance of 5.5% to 6%, but missed analysts’ expectations of 6.3%.
Siemens Healthineers raised its dividend to 1 euro per share from 0.95 euros per share last year and expects comparable revenue growth to be between 5% to 6% in 2026, it said in the statement.
($1 = 0.8575 euros)
(Reporting by Alexander Huebner in Munich and Marleen Kaesebier in Gdansk; editing by Milla Nissi-Prussak and Matt Scuffham)
